Cargando…

TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice

BACKGROUND & AIMS: Toll-like receptor 4 (TLR4) signaling is activated through 2 adaptor proteins: MyD88 and TIR-domain containing adaptor-inducing interferon-β (TRIF). TLR4 and MyD88 are crucial in nonalcoholic steatohepatitis (NASH) and fibrosis. However, the role of TRIF in TLR4-mediated NASH ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ling, Miura, Kouichi, Zhang, Bi, Matsushita, Hiroshi, Yang, Yoon Mee, Liang, Shuang, Song, Jingyi, Roh, Yoon Seok, Seki, Ekihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403956/ https://www.ncbi.nlm.nih.gov/pubmed/28462384 http://dx.doi.org/10.1016/j.jcmgh.2016.12.004

Ejemplares similares

TAK1: A Molecular Link Between Liver Inflammation, Fibrosis, Steatosis, and Carcinogenesis
por: Wang, Weijun, et al.
Publicado: (2021)

TRIF as a Novel Modulator of Liver Inflammation and Fibrosis
por: Török, Natalie J.
Publicado: (2017)

Toll-Like Receptors in Liver Fibrosis: Cellular Crosstalk and Mechanisms
por: Yang, Ling, et al.
Publicado: (2012)

Neurotropin Suppresses Inflammatory Cytokine Expression and Cell Death through Suppression of NF-κB and JNK in Hepatocytes
por: Zhang, Bi, et al.
Publicado: (2014)

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1
por: Czech, Torrey Y., et al.
Publicado: (2018)

Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease
por: Miura, Kouichi, et al.
Publicado: (2010)

FAP: Not Just a Biomarker but Druggable Target in Liver Fibrosis
por: Kim, Jieun, et al.
Publicado: (2023)

Hepatic Fibrosis and Steatosis in Metabolic Syndrome
por: Gangireddy, Venu Gopala Reddy, et al.
Publicado: (2022)

Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis
por: Xie, Yan, et al.
Publicado: (2021)

Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children
por: Shin, Hyun Joo, et al.
Publicado: (2018)

Hyaluronan in liver fibrosis: basic mechanisms, clinical implications, and therapeutic targets
por: Kim, Jieun, et al.
Publicado: (2023)

TAK1-dependent autophagy: A suppressor of fatty liver disease and hepatic oncogenesis
por: Seki, Ekihiro
Publicado: (2014)

In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
por: Lee, Young-Sun, et al.
Publicado: (2023)

Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis
por: Yang, Yoon Mee, et al.
Publicado: (2018)

Hepatic steatosis and fibrosis: Non-invasive assessment
por: Karanjia, Rustam N, et al.
Publicado: (2016)

Toll-Like Receptor Signaling and Liver Fibrosis
por: Aoyama, Tomonori, et al.
Publicado: (2010)

Hyaluronan synthase 2, a target of miR-200c, promotes carbon tetrachloride-induced acute and chronic liver inflammation via regulation of CCL3 and CCL4
por: Kim, Sun Myoung, et al.
Publicado: (2022)

Inhibition of TRIF-Dependent Inflammation Decelerates Afterload-Induced Myocardial Remodeling
por: Bettink, Stephanie I., et al.
Publicado: (2022)

Hepatitis C Virus (HCV) Infection and Hepatic Steatosis
por: Yoon, Eugene J., et al.
Publicado: (2006)

The association of hepatic steatosis and fibrosis with heart failure and mortality
por: Park, Jiyun, et al.
Publicado: (2021)

Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease
por: Veltkamp, Claudia, et al.
Publicado: (2022)

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways
por: Lee, Seung Min, et al.
Publicado: (2022)

TRIF Deficiency does not Affect Severity of Ovalbumin-induced Airway Inflammation in Mice
por: Kim, Tae-Hyoun, et al.
Publicado: (2014)

IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
por: Gao, Yinjie, et al.
Publicado: (2016)

Basic and Clinical Advances in Chronic Liver Inflammation
por: Enomoto, Hirayuki, et al.
Publicado: (2016)

Kupffer Cell TLR2/3 Signaling: A Pathway for EGCG Amelioration of Ethanol-Induced Hepatic Injury
por: Czech, Torrey Y., et al.
Publicado: (2019)

Gentiopicroside Ameliorates the Progression from Hepatic Steatosis to Fibrosis Induced by Chronic Alcohol Intake
por: Yang, Hong-Xu, et al.
Publicado: (2020)

Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
por: McCommis, Kyle S., et al.
Publicado: (2018)

GIV/Girdin is a central hub for pro-fibrogenic signalling networks during liver fibrosis
por: Lopez-Sanchez, Inmaculada, et al.
Publicado: (2014)

Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity
por: Garibay-Nieto, Nayely, et al.
Publicado: (2023)

Retraction: TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling
Publicado: (2021)

Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells
por: Siegmund, Sören V., et al.
Publicado: (2016)

The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice
por: Wang, Xiaoxin X., et al.
Publicado: (2022)

The Association between Low Muscle Mass and Hepatic Steatosis in Asymptomatic Population in Korea
por: Chung, Goh-Eun, et al.
Publicado: (2021)

Melatonin Alleviates PM(2.5)-Induced Hepatic Steatosis and Metabolic-Associated Fatty Liver Disease in ApoE(−/−) Mice
por: Du, Zhou, et al.
Publicado: (2022)

Acrolein, a New Villain in the Development of Alcoholic Liver Disease
por: Seki, Ekihiro
Publicado: (2016)

Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation
por: Wang, Yuanli, et al.
Publicado: (2022)

OR27-2 Growth Hormone Reduces Hepatic Steatosis, Inflammation and Fibrosis in Adults with Overweight/Obesity and Nonalcoholic Fatty Liver Disease
por: Bartsch, Lea, et al.
Publicado: (2022)

Inhibition of Heme Oxygenase Antioxidant Activity Exacerbates Hepatic Steatosis and Fibrosis In Vitro
por: Raffaele, Marco, et al.
Publicado: (2019)

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
por: Kutney, Katherine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lli7vk2uqnursqln9smu8v02ad